復星醫藥(02196.HK)增資復雲健康獲56.7%股權
復星醫藥(02196.HK)公布,附屬復星健康、寧波復技與海南雲志及目標公司復雲健康及其股東復星高科技訂立增資協議,包括向目標公司增資,其中復星健康、寧波復技、海南雲志擬分別現金出資850萬元人民幣(下同)、850萬元、300萬元認繳目標公司等值新增註冊資本。
本次增資完成後,復星醫藥透過復星健康及寧波復技合共持有復雲健康約56.6666%股權,將成為公司附屬。
復雲健康專注於打造針對老年和慢病群體的健康管理服務平台,核心產品為星衛士智能手錶。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.